Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere Therapeutics, Inc. (TVTX) shares are trading higher on Wednesday after the company announced that it was informed by ...

Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on ...

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, ...

If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by ...

Travere Therapeutics (TVTX) has witnessed significant developments, including the FDA's decision not to call an advisory committee meeting for the sNDA of FILSPARI®, while the drug is still under ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Travere Therapeutics TVTX is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX) in the last three months. The table below provides a snapshot ...

Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. Travere recently sold two of its drugs for $445 million.